22 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 12 Phase 2, 8 Phase 1, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 11, Terminated 1 |
| Phase 1 | 8 | Completed 6, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 4 |
| Not applicable | 1 | Completed 1 |
Follow Allergy Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GRASS (Grass MATA MPL Real-world Assessment Study) Grassmuno® - Grass Pollen Allergy | Recruiting | Allergy Therapeutics | 1000 | 2026-03-11 | 2026-03-20 | |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects VLP Peanut, Placebo - Peanut Allergy | Phase 1 | Active not recruiting | Allergy Therapeutics | 46 | 2022-10-17 | 2026-03-13 |
| Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen PQ Grass, Placebo - Seasonal Allergic Rhinitis, Rhinoconjunctivitis | Phase 3 | Completed | Allergy Therapeutics | 555 | 2022-10-11 | 2025-04-02 |
| Effect of holoBLG on Cat Allergic Patients holoBLG - Allergy to Cats, Allergic Rhinoconjunctivitis | Not applicable | Completed | Allergy Therapeutics | 42 | 2021-10-04 | 2023-12-18 |
| Tyrosine Allergoid Paediatric and Adult Study MATA trees or MATA grass - Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis | Active not recruiting | Allergy Therapeutics | 320 | 2020-11-06 | 2026-01-30 | |
| An Exploratory Study of PQ Grass 27600 SU PQ Grass, Active Placebo, Standard Placebo - Rhinitis, Allergic, Seasonal | Phase 2 / Phase 3 | Completed | Allergy Therapeutics | 119 | 2020-10-19 | 2026-04-29 |
| Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels Pollinex Quattro with tree- and grass pollen extracts and their mixtures - Rhinitis, Allergic, Respiratory Tract Infections | Completed | Allergy Therapeutics | 113 | 2020-04-22 | 2021-02-08 | |
| A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL Placebo comparator, Grass MATA MPL - Seasonal Allergic Rhinitis | Phase 1 | Completed | Allergy Therapeutics | 30 | 2017-01-16 | 2019-04-30 |
| Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™ Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU - Seasonal Allergic Rhinitis | Phase 2 | Completed | Allergy Therapeutics | 265 | 2015-11-07 | 2021-01-29 |
| A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo - Allergic Rhinitis | Phase 1 | Completed | Allergy Therapeutics | 29 | 2015-08-01 | 2017-03-03 |
| Efficacy and Safety/Tolerability of Ragweed MATA MPL Ragweed MATA MPL - Type I Hypersensitivity | Phase 3 | Completed | Allergy Therapeutics | 993 | 2007-03-01 | 2010-06-17 |
| Efficacy and Safety/Tolerability of Grass MATA MPL Grass MATA MPL, Placebo - Type I Hypersensitivity | Phase 3 | Completed | Allergy Therapeutics | 1028 | 2006-11-01 | 2010-06-17 |
| Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis Tree MATA MPL or Tree MATA - Type I Hypersensitivity | Phase 2 | Terminated | Allergy Therapeutics | 121 | 2006-10-01 | 2020-11-30 |
| Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis Ragweed MATAMPL - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 100 | 2006-05-01 | 2010-06-17 |
| Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen OralvacB2MPL - Type I Hypersensitivity | Phase 1 | Completed | Allergy Therapeutics | 86 | 2005-12-01 | 2010-06-17 |
| Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test RagweedMATAMPL - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 69 | 2005-11-01 | 2021-06-11 |
| Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen Grass MATAMPL - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 68 | 2005-09-12 | 2021-05-18 |
| Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine Grass MATA MPL - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 41 | 2005-09-12 | 2021-07-13 |
| Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen Tree MATA MPL - Therapeutic Regimen, Tree MATA MPL - Intermediate dose, Tree MATA MPL - Low dose - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 68 | 2005-07-07 | 2021-02-09 |
| Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen TreeMATA MPL - Type I Hypersensitivity | Phase 2 | Completed | Allergy Therapeutics | 70 | 2005-07-01 | 2010-06-17 |
Showing 20 of 27. Sign in to see all of them.
Hypersensitivity (20) · Hypersensitivity, Immediate (17) · Rhinitis, Allergic, Seasonal (5) · Conjunctivitis, Allergic (2) · Rhinitis, Allergic (2) · Peanut Hypersensitivity (1) · Respiratory Tract Infections (1)
ragweed MATA MPL (2) · Pollinex Quattro (1)
Canada (12) · United States (12) · Germany (7) · Austria (2) · Czechia (1) · Hungary (1) · Poland (1) · United Kingdom (1)
Deepen Patel, MD (5) · Deepen Patel, MD, CCFP (1) · Karl-Christian Bergmann, Prof. Dr. med. (1) · Kemi Oluwayi, MD (1) · Michael J. Noonan, MD (1) · Paul H. Ratner, MD (1) · Pieter-Jan De Kam, PhD (1) · Pieter-Jan de Kam, Ph.D (1) · Ralph Moesges, Prof. (1) · Tim Higenbottam, DSc MD FRCP (1) · Tim Higenbottam, DSc MD FRCP FFPM (1) · Tim Higenbottam, MD, FRCP (1) · Wolfgang Timmer, MD (1)
PMID 40626378, PMID 23062390, PMID 37488734, PMID 39756833
2019 (1)